Tumor Agnostic Role of TMB Biomarker Faces Challenges
OncLive,
Although tumor mutational burden is established as a clinically informative feature of tumors, its optimal use in therapeutic…
Although tumor mutational burden is established as a clinically informative feature of tumors, its optimal use in therapeutic…
Abstract Immune checkpoint inhibitors (ICIs) have made important breakthrough in anti-tumor therapy, however, no single…
Dan Brudzewsky, PhD Senior Field Applications Scientist - UK
Advertisement “Next-generation sequencing may help identify who is going to respond to single-agent therapy with low toxicities…